Skip to main content
All lobbying clients

AGIOS PHARMACEUTICALS

Lobbying client · Massachusetts · filed 2025 to 2026

Biotech/biopharmaceutical company

$240,000 Reported spend
15 Filings counted
2 Outside firms hired
2 Bills named

Spend is reported income plus in-house expenses across 15 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 3 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as AGIOS PHARMACEUTICALS, INC.

 Who filed for this client 3

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 2
  • H.R. 5094
    Protect Patients from Costly Care Act
    2 filings
  • H.R. 5187
    To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufa…
    2 filings
 Reported by year 2 years
  • 2026 $180,000 9 filings
  • 2025 $60,000 6 filings
 Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • HOUSE OF REPRESENTATIVES 12
  • SENATE 12
 Recent filings 15 total
Q3 report
GRIDIRON PUBLIC AFFAIRS, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 19, 2026
View → Q3 report
AGIOS PHARMACEUTICALS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 expenses · posted Oct 19, 2026
View → Q3 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $10,000 income · posted Oct 18, 2026
View → Q2 report
AGIOS PHARMACEUTICALS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $30,000 expenses · posted Jul 20, 2026
View → Q2 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $10,000 income · posted Jul 20, 2026
View → Q2 report
GRIDIRON PUBLIC AFFAIRS, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $10,000 income · posted Jul 16, 2026
View → Registration
GRIDIRON PUBLIC AFFAIRS, LLC
2nd Quarter 2026 (Apr 1 - June 30) · posted May 26, 2026
View → Q1 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $10,000 income · posted Apr 20, 2026
View → Q1 report
AGIOS PHARMACEUTICALS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $70,000 expenses · posted Apr 17, 2026
View → Q4 report
JEFFREY J. KIMBELL & ASSOCIATES, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $10,000 income · posted Jan 20, 2026
View → Q4 report
AGIOS PHARMACEUTICALS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $20,000 expenses · posted Jan 20, 2026
View → Registration
JEFFREY J. KIMBELL & ASSOCIATES, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 9, 2026
View → Q3 report
AGIOS PHARMACEUTICALS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $10,000 expenses · posted Oct 17, 2025
View → Q2 amendment
AGIOS PHARMACEUTICALS
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $20,000 expenses · posted Jul 22, 2025
View → Registration
AGIOS PHARMACEUTICALS
2nd Quarter 2025 (Apr 1 - June 30) · posted Jun 12, 2025
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem